💊 Drugs get costlier in India; J&J launches allergy-fighting lens; HBR overstates our importance to robots

Mar 03, 2022

∙ Paid

In today’s Kable: Common medicines likely to get costlier in India; Success and Mankind; Pfizer gets generous with Paxlovid; WHO says Covid infections declining, Hong Kong disagrees; Roche starts a trial for its Alzheimer’s drug we think; and happy Friday to all.

Keep reading with a 7-day free trial

Subscribe to The Kable to keep reading this post and get 7 days of free access to the full post archives.